IBDEI3BL ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1619,0)
 ;;=PREGNANCY COMPLICATIONS^21^126
 ;;^UTILITY(U,$J,358.4,1620,0)
 ;;=PREGNANCY-HYPERTENSION^24^126
 ;;^UTILITY(U,$J,358.4,1621,0)
 ;;=PREGNANCY-VOMITING^27^126
 ;;^UTILITY(U,$J,358.4,1622,0)
 ;;=LATE PREGNANCY^15^126
 ;;^UTILITY(U,$J,358.4,1623,0)
 ;;=PREGNANCY-OTH COMPLICATIONS^25^126
 ;;^UTILITY(U,$J,358.4,1624,0)
 ;;=PREGNANCY CONDITIONS^22^126
 ;;^UTILITY(U,$J,358.4,1625,0)
 ;;=MULTIPLE GESTATIONS^18^126
 ;;^UTILITY(U,$J,358.4,1626,0)
 ;;=PREGNANCY-FETAL ABNORMALITY^23^126
 ;;^UTILITY(U,$J,358.4,1627,0)
 ;;=AMNIO/MEMBRANE PROBLEMS^3^126
 ;;^UTILITY(U,$J,358.4,1628,0)
 ;;=MAJOR PUERPERAL INFECTIONS^16^126
 ;;^UTILITY(U,$J,358.4,1629,0)
 ;;=VENOUS COMPLICATIONS^33^126
 ;;^UTILITY(U,$J,358.4,1630,0)
 ;;=PREGNANCY-PYREXIA^26^126
 ;;^UTILITY(U,$J,358.4,1631,0)
 ;;=PUERPERIUM COMPLICATIONS^29^126
 ;;^UTILITY(U,$J,358.4,1632,0)
 ;;=INFECTION-BREAST/NIPPLE IN PREGNANCY^12^126
 ;;^UTILITY(U,$J,358.4,1633,0)
 ;;=PREGNANCY-Z CODES^28^126
 ;;^UTILITY(U,$J,358.4,1634,0)
 ;;=GENITOURINARY & RENAL^11^126
 ;;^UTILITY(U,$J,358.4,1635,0)
 ;;=DIGESTIVE^9^126
 ;;^UTILITY(U,$J,358.4,1636,0)
 ;;=VAGINA^32^126
 ;;^UTILITY(U,$J,358.4,1637,0)
 ;;=VULVA^34^126
 ;;^UTILITY(U,$J,358.4,1638,0)
 ;;=UTERUS^31^126
 ;;^UTILITY(U,$J,358.4,1639,0)
 ;;=PREGNANCY^20^126
 ;;^UTILITY(U,$J,358.4,1640,0)
 ;;=PAIN SYNDROME^19^126
 ;;^UTILITY(U,$J,358.4,1641,0)
 ;;=MENOPAUSE^17^126
 ;;^UTILITY(U,$J,358.4,1642,0)
 ;;=INFERTILITY^14^126
 ;;^UTILITY(U,$J,358.4,1643,0)
 ;;=ENDOCRINE^10^126
 ;;^UTILITY(U,$J,358.4,1644,0)
 ;;=INFECTION-D/C & PARASITIC DISEASES^13^126
 ;;^UTILITY(U,$J,358.4,1645,0)
 ;;=DERMATOLOGY^8^126
 ;;^UTILITY(U,$J,358.4,1646,0)
 ;;=CONTRACEPTION-HRT^7^126
 ;;^UTILITY(U,$J,358.4,1647,0)
 ;;=CERVICAL^6^126
 ;;^UTILITY(U,$J,358.4,1648,0)
 ;;=BREAST^5^126
 ;;^UTILITY(U,$J,358.4,1649,0)
 ;;=BLEEDING (NON-PREGNANT)^4^126
 ;;^UTILITY(U,$J,358.4,1650,0)
 ;;=ADNEXA^2^126
 ;;^UTILITY(U,$J,358.4,1651,0)
 ;;=GENERAL-GLOBAL^1^126
 ;;^UTILITY(U,$J,358.4,1652,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^30^126
 ;;^UTILITY(U,$J,358.4,1653,0)
 ;;=ESTABLISHED PATIENT^1^127
 ;;^UTILITY(U,$J,358.4,1654,0)
 ;;=NEW PATIENT^2^127
 ;;^UTILITY(U,$J,358.4,1655,0)
 ;;=CONSULTATION^3^127
 ;;^UTILITY(U,$J,358.4,1656,0)
 ;;=DIABETES TYPE 2/TYPE 1^16^128
 ;;^UTILITY(U,$J,358.4,1657,0)
 ;;=GLAUCOMA-LTG/PIGMENT/PSEUDOEX^20^128
 ;;^UTILITY(U,$J,358.4,1658,0)
 ;;=LENS/CATARACT^7^128
 ;;^UTILITY(U,$J,358.4,1659,0)
 ;;=LIDS/LASHES/DRY EYE^4^128
 ;;^UTILITY(U,$J,358.4,1660,0)
 ;;=MACULA^8^128
 ;;^UTILITY(U,$J,358.4,1661,0)
 ;;=RETINA-VASCULAR^10^128
 ;;^UTILITY(U,$J,358.4,1662,0)
 ;;=REFRACTIVE/VF/OTHER^3^128
 ;;^UTILITY(U,$J,358.4,1663,0)
 ;;=CATEGORIES OF VISION LOSS^2^128
 ;;^UTILITY(U,$J,358.4,1664,0)
 ;;=GLOBE/ORBIT/PAIN^13^128
 ;;^UTILITY(U,$J,358.4,1665,0)
 ;;=MOST FREQUENT^1^128
 ;;^UTILITY(U,$J,358.4,1666,0)
 ;;=CONJUNCTIVA/SCLERA^5^128
 ;;^UTILITY(U,$J,358.4,1667,0)
 ;;=CORNEA/PUPILS/IRIS^6^128
 ;;^UTILITY(U,$J,358.4,1668,0)
 ;;=GLAUCOMA-OPEN ANGLE^19^128
 ;;^UTILITY(U,$J,358.4,1669,0)
 ;;=GLAUCOMA-SUSPECT/OHTN^18^128
 ;;^UTILITY(U,$J,358.4,1670,0)
 ;;=GLAUCOMA-OTHER^21^128
 ;;^UTILITY(U,$J,358.4,1671,0)
 ;;=MACULA-AMD^9^128
 ;;^UTILITY(U,$J,358.4,1672,0)
 ;;=CHOROID/RETINA/RD^11^128
 ;;^UTILITY(U,$J,358.4,1673,0)
 ;;=VITREOUS^12^128
 ;;^UTILITY(U,$J,358.4,1674,0)
 ;;=OPTIC NERVE/VISUAL PATHWAY^14^128
 ;;^UTILITY(U,$J,358.4,1675,0)
 ;;=NEURO/STRABISMUS/EYE MOVEMENT^15^128
